ArticleFrontiers in medicine2026
Machine learning model for ACLF risk in decompensated cirrhosis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop a machine learning-based predictive model for acute-on-chronic liver failure (ACLF) risk in patients with decompensated cirrhosis using baseline clinical indicators at hospital admission. Materials and methods: This retrospective cohort included 360 decompensated cirrhosis patients with intensive monitoring needs or infection/circulatory risk factors, randomly divided into training and validation sets at a 7:3 ratio. Three models-random forest, support vector machine, and logistic regression-were constructed. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA). SHapley Additive exPlanations (SHAP) were employed for model interpretability. Results: In the training set, 52 patients (20.6%) experienced ACLF. Multivariate analysis identified total bilirubin (TBil) (OR = 1.051, 95% CI: 1.030-1.073, Conclusion: The random forest model showed acceptable training performance, but the wide validation AUC confidence interval suggests limited stability, likely due to small sample size and few events. External validation is needed before clinical use. Nonetheless, the model shows potential for early warning and risk stratification in decompensated cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.